Skip to content
TrialScanner

NCT02742090

Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

Phase 2TerminatedTGTXLead

Registry record

Lead sponsor
TG Therapeutics, Inc.
Conditions
Chronic Lymphocytic Leukemia
Primary completion
Jun 10, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02742090 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02742090: Evaluate the Efficacy and... | TrialScanner